company background image
DCPH logo

Deciphera Pharmaceuticals NasdaqGS:DCPH Stok Raporu

Son Fiyat

US$25.59

Piyasa Değeri

US$2.2b

7D

0.08%

1Y

76.5%

Güncellenmiş

11 Jun, 2024

Veri

Şirket Finansalları +

Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Stok Raporu

Piyasa değeri: US$2.2b

DCPH Stoklara Genel Bakış

A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.

Deciphera Pharmaceuticals, Inc. Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Deciphera Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$25.59
52 Haftanın En Yüksek SeviyesiUS$25.61
52 Haftanın En Düşük SeviyesiUS$9.90
Beta0.18
11 Aylık Değişim0.91%
3 Aylık Değişim60.14%
1 Yıllık Değişim76.48%
33 Yıllık Değişim-28.68%
5 Yıllık Değişim6.71%
Halka arzdan bu yana değişim44.99%

Son Haberler & Güncellemeler

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Hissedar Getirileri

DCPHUS BiotechsUS Pazar
7D0.08%-1.4%-1.9%
1Y76.5%20.2%30.4%

Getiri vs. Endüstri: DCPH geçen yıl % 20.2 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: DCPH geçen yıl % 30.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is DCPH's price volatile compared to industry and market?
DCPH volatility
DCPH Average Weekly Movement20.9%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

İstikrarlı Hisse Senedi Fiyatı: DCPH hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: DCPH 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 12% dan 21% a yükseldi.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2003355Steve Hoerterwww.deciphera.com

Deciphera Pharmaceuticals, Inc. Temel Bilgiler Özeti

Deciphera Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DCPH temel i̇stati̇sti̇kler
Piyasa değeriUS$2.21b
Kazançlar(TTM)-US$190.42m
Gelir(TTM)US$174.91m

12.7x

P/S Oranı

-11.6x

F/K Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DCPH gelir tablosu (TTM)
GelirUS$174.91m
Gelir MaliyetiUS$242.52m
Brüt Kâr-US$67.61m
Diğer GiderlerUS$122.80m
Kazançlar-US$190.42m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-2.20
Brüt Marj-38.66%
Net Kâr Marjı-108.87%
Borç/Özkaynak Oranı0%

DCPH uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün